This study found that brand price at launch and generic entry overstates long-run average pharmaceutical costs, with and without accounting for medical cost offsets.
Adrian Towse, MA, MPhil
Advertisement
Articles by Adrian Towse, MA, MPhil
Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
Advertisement
Latest Updated Articles
- Private Sector Risk-Sharing Agreements in the United States: Trends, Barriers, and Prospects
Published: September 15th 2015 | Updated:
- What Do Pharmaceuticals Really Cost in the Long Run?
Published: August 22nd 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
3
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
4
Aggressive Therapy Recommendations Following the STRONG-HF Trials: Stephen J. Green, MD
5
